Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.)

Overview


Plain-Language Overview

Tinea, also known as dermatophytosis, is a common fungal infection that affects the skin, hair, and nails. It is caused by fungi called dermatophytes, which include species from the genera Trichophyton, Microsporum, and Epidermophyton. These fungi thrive on keratin, a protein found in the outer layer of the skin, leading to itchy, red, scaly patches that can be uncomfortable and sometimes painful. The infection can appear in various body areas, such as the feet (athlete’s foot), groin (jock itch), scalp, or body. It spreads easily through direct contact with infected people, animals, or contaminated objects. While not life-threatening, tinea can significantly affect quality of life due to its symptoms and contagious nature.

Clinical Definition

Tinea (dermatophytosis) is a superficial fungal infection caused by keratinophilic dermatophytes, primarily species of Trichophyton, Microsporum, and Epidermophyton. These fungi invade the stratum corneum of the epidermis, hair shafts, and nails, leading to characteristic erythematous, scaly plaques with central clearing and peripheral active borders. The infection is transmitted via direct contact with infected humans, animals, or fomites. Clinically, tinea presents with localized or widespread lesions depending on the site and host immune response. It is significant due to its high prevalence, potential for chronicity, and secondary bacterial infections. Diagnosis relies on clinical features supported by laboratory confirmation. Untreated infections can cause persistent discomfort and cosmetic concerns.

Inciting Event

  • Direct contact with infected skin, hair, or fomites initiates infection.

  • Exposure to contaminated soil or animals harboring dermatophytes can trigger infection.

  • Microtrauma or skin barrier disruption facilitates fungal entry.

  • Use of shared towels, clothing, or footwear can transmit spores.

  • Excessive sweating or moisture accumulation creates a favorable environment for fungal growth.

Latency Period

  • Symptoms typically develop within 1 to 2 weeks after exposure to infectious spores.

  • Incubation can vary from several days to weeks depending on fungal load and host immunity.

  • Chronic infections may persist for months without treatment due to slow fungal growth.

  • Initial asymptomatic colonization may delay symptom onset.

  • Latency is shorter in immunocompromised hosts due to rapid fungal proliferation.

Diagnostic Delay

  • Early lesions may be mistaken for eczema or psoriasis due to nonspecific scaling and erythema.

  • Patients often self-treat with topical corticosteroids, which can mask symptoms and worsen infection.

  • Lack of awareness about fungal infections leads to delayed medical evaluation.

  • Misdiagnosis as bacterial cellulitis or allergic dermatitis can delay appropriate antifungal therapy.

  • Subtle or atypical presentations in immunocompromised patients complicate diagnosis.

Clinical Presentation


Signs & Symptoms

  • Pruritic, annular, scaly plaques with central clearing and raised borders are hallmark symptoms.

  • Scaling, fissuring, and maceration commonly affect interdigital spaces in tinea pedis.

  • Hair loss with broken hairs and scalp scaling occurs in tinea capitis.

  • Nail thickening and discoloration are typical in onychomycosis.

  • Mild erythema and inflammation often accompany lesions.

History of Present Illness

  • Patients report pruritic, scaly, annular plaques with central clearing and raised borders.

  • Lesions often begin as small, red, scaly patches that expand centrifugally over days to weeks.

  • Symptoms include itching, burning, and sometimes mild pain at the affected site.

  • Chronic untreated lesions may develop hyperpigmentation or lichenification.

  • Involvement of nails (onychomycosis) presents with thickened, discolored, and brittle nails.

Past Medical History

  • History of previous dermatophyte infections increases risk of recurrence.

  • Use of immunosuppressive medications or presence of immunodeficiency disorders predisposes to severe disease.

  • Chronic conditions causing excessive sweating such as diabetes mellitus may contribute.

  • Prior topical corticosteroid use on affected areas can exacerbate infection.

  • History of athlete’s foot or tinea pedis is common in patients with tinea corporis or cruris.

Family History

  • Family members often share similar fungal infections due to close contact and shared environments.

  • No known genetic predisposition or heritable syndromes are associated with dermatophytosis.

  • Household clustering is common due to fomite transmission and direct skin contact.

  • Family history of atopic dermatitis may complicate clinical presentation but is not causative.

  • Awareness of infected household contacts aids in diagnosis and prevention.

Physical Exam Findings

  • Annular, scaly plaques with central clearing and an advancing, raised border are characteristic of tinea corporis.

  • Erythematous, scaly patches with possible vesicles or pustules are common in tinea pedis.

  • Thickened, discolored, and brittle nails indicate onychomycosis caused by dermatophytes.

  • Hair shaft invasion with broken hairs and black dots is seen in tinea capitis.

  • Pruritus and mild erythema are frequent findings in affected skin areas.

Diagnostic Workup


Diagnostic Criteria

Diagnosis of tinea is established by clinical examination revealing annular, scaly plaques with central clearing and active borders. Confirmation requires microscopic identification of septate hyphae in skin scrapings using potassium hydroxide (KOH) preparation. Fungal culture on Sabouraud agar can identify the specific dermatophyte species. Wood’s lamp examination may aid diagnosis in some Microsporum infections by showing fluorescence. Histopathology is rarely needed but shows fungal elements in the stratum corneum.

Pathophysiology


Key Mechanisms

  • Keratinophilic dermatophytes such as Trichophyton, Microsporum, and Epidermophyton invade and digest keratinized tissues including skin, hair, and nails.

  • Fungal hyphae proliferate within the stratum corneum, triggering a host inflammatory response that causes erythema and scaling.

  • Enzymatic degradation of keratin by fungal keratinases facilitates tissue invasion and persistence.

  • The infection remains superficial due to the fungi's inability to invade living deeper tissues or elicit systemic immune responses.

  • Delayed-type hypersensitivity reactions contribute to the characteristic pruritus and inflammation.

InvolvementDetails
Organs

Skin is the primary organ affected by tinea, showing characteristic scaling and inflammation.

Nails can be involved in onychomycosis, a chronic fungal infection of the nail plate.

Tissues

Stratum corneum is the outermost skin layer where dermatophytes colonize and degrade keratin.

Epidermis provides the barrier and immune environment involved in fungal defense.

Cells

Keratinocytes serve as the primary site of fungal invasion and produce antimicrobial peptides in response.

Langerhans cells present fungal antigens to initiate adaptive immune responses.

Neutrophils infiltrate infected tissue to phagocytose fungi and release reactive oxygen species.

Chemical Mediators

Interleukin-17 (IL-17) is critical for recruiting neutrophils and controlling dermatophyte infection.

Tumor necrosis factor-alpha (TNF-α) promotes inflammation and fungal clearance.

Defensins are antimicrobial peptides produced by keratinocytes that inhibit fungal growth.

Treatments


Pharmacological Treatments

  • Terbinafine

    • Mechanism:
      • Inhibits squalene epoxidase, disrupting fungal cell membrane synthesis.

    • Side effects:
      • Gastrointestinal upset

      • Rash

      • Elevated liver enzymes

    • Clinical role:
      • First-line

  • Itraconazole

    • Mechanism:
      • Inhibits fungal lanosterol 14α-demethylase, impairing ergosterol synthesis.

    • Side effects:
      • Hepatotoxicity

      • Heart failure exacerbation

      • Drug interactions

    • Clinical role:
      • Second-line

  • Griseofulvin

    • Mechanism:
      • Disrupts fungal mitotic spindle by binding to microtubules, inhibiting cell division.

    • Side effects:
      • Photosensitivity

      • Headache

      • Hepatotoxicity

    • Clinical role:
      • Second-line

  • Topical azoles (e.g., clotrimazole, miconazole)

    • Mechanism:
      • Inhibit fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis locally.

    • Side effects:
      • Local irritation

      • Contact dermatitis

    • Clinical role:
      • First-line

  • Topical allylamines (e.g., terbinafine cream)

    • Mechanism:
      • Inhibit squalene epoxidase locally, causing fungal cell membrane disruption.

    • Side effects:
      • Local irritation

      • Pruritus

    • Clinical role:
      • First-line

Non-pharmacological Treatments

  • Keep affected skin clean and dry to reduce fungal growth.

  • Avoid sharing personal items such as towels and clothing to prevent transmission.

  • Wear breathable, loose-fitting clothing to minimize moisture retention.

  • Regularly disinfect footwear and socks to reduce fungal reservoirs.

Prevention


Pharmacological Prevention

  • Topical antifungals such as terbinafine or clotrimazole applied to at-risk skin prevent recurrence.

  • Oral antifungal prophylaxis may be used in immunocompromised patients with recurrent infections.

  • Antifungal powders or sprays reduce moisture and fungal colonization in interdigital spaces.

Non-pharmacological Prevention

  • Maintaining dry, clean skin and avoiding occlusive footwear reduce fungal growth.

  • Avoiding sharing personal items like towels and shoes prevents transmission.

  • Wearing breathable clothing and changing socks frequently decreases moisture retention.

  • Regular foot hygiene and drying between toes prevent tinea pedis.

  • Screening and treating household contacts reduce reinfection risk.

Outcome & Complications


Complications

  • Secondary bacterial cellulitis can develop from skin barrier disruption.

  • Chronic dermatophytosis may cause persistent inflammation and lichenification.

  • Allergic reactions such as dermatophytid (id) reactions can occur distant from primary lesions.

  • Scarring alopecia may result from severe tinea capitis.

Short-term Sequelae Long-term Sequelae
  • Intense pruritus and discomfort leading to scratching and excoriations.

  • Acute inflammation and erythema at infected sites.

  • Superimposed bacterial infection causing pain and swelling.

  • Temporary hair loss in affected scalp areas.

  • Chronic skin changes including hyperpigmentation or hypopigmentation.

  • Permanent nail dystrophy from untreated onychomycosis.

  • Scarring alopecia after severe or untreated tinea capitis.

  • Recurrent or persistent infections due to incomplete eradication.

Differential Diagnoses


Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.) versus Psoriasis

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.)

Psoriasis

Annular, scaly plaques with central clearing and advancing border

Well-demarcated, thick, silvery-white scaly plaques

Hairline, groin, feet, and other keratinized skin areas

Extensor surfaces, scalp, and nails

Usually absent or minimal nail changes

Pitting, onycholysis, and oil spots

Requires antifungal agents for resolution

Improves with topical corticosteroids and vitamin D analogs

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.) versus Seborrheic dermatitis

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.)

Seborrheic dermatitis

Dry, white or gray scales with sharply demarcated edges

Greasy, yellowish scales on erythematous base

Feet, groin, and other keratinized skin areas

Scalp, nasolabial folds, eyebrows, and chest

Caused by dermatophyte fungi of Trichophyton, Microsporum, or Epidermophyton

Associated with Malassezia yeast overgrowth

Requires systemic or topical antifungals targeting dermatophytes

Responds to antifungal shampoos and mild corticosteroids

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.) versus Pityriasis rosea

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.)

Pityriasis rosea

Annular plaques with active, scaly borders and central clearing

Herald patch followed by Christmas-tree distribution of oval plaques

Chronic or recurrent without spontaneous resolution

Self-limited, resolving within 6-8 weeks

Fungal infection by dermatophytes

Likely viral (HHV-6/7) etiology

Requires antifungal therapy for cure

Symptomatic treatment only, no antifungals needed

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.) versus Nummular eczema

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.)

Nummular eczema

Annular plaques with raised scaly borders and central clearing

Coin-shaped, eczematous plaques with oozing and crusting

Pruritus variable but often present

Severe itching common

Fungal hyphae visible on KOH prep or biopsy

Spongiosis and epidermal hyperplasia without fungal elements

Requires antifungal agents for resolution

Improves with topical corticosteroids and emollients

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.) versus Candidiasis

Tinea (Dermatophytosis - Trichophyton, Microsporum, Epidermophyton spp.)

Candidiasis

Annular plaques with sharply demarcated scaly borders

Erythematous plaques with satellite pustules

Keratinized skin areas like feet, groin, scalp

Intertriginous areas, mucous membranes

Septate hyphae and arthroconidia of dermatophytes

Yeast and pseudohyphae of Candida albicans

Responds to antifungals targeting dermatophytes (terbinafine, griseofulvin)

Responds to antifungals targeting yeasts (azoles, nystatin)

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.